MedTrace Logo

Amobarbital and Cardiopulmonary Bypass

NCT06757868 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-03-21

No results posted yet for this study

Summary

Explore the effects of amobarbital on myocardial protection and prognosis in patients undergoing cardiac surgery with cardiopulmonary bypass, investigate the new usage of old drugs, and provide reliable clinical scientific basis for its potential value in better clinical treatment.

Conditions

  • Cardiopulmonary Bypass

Interventions

DRUG

Amobarbital

Amobarbital 1mg/kg is given prior to cardiopulmonary bypass

DRUG

Midazolam

midazolam 0.1mg/kg is given prior to cardiopulmonary bypass

Sponsors & Collaborators

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • Aihua Du, Dr · Tongji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-01
Primary Completion
2025-12-31
Completion
2026-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06757868 on ClinicalTrials.gov